Monjuvi

Active Ingredient(s): Tafasitamab-cxix
FDA Approved: * July 31, 2020
Pharm Company: * MORPHOSYS US INC
Category: Cancer

Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1] Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby.[2] The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swellin... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.